Cullen Capital Management LLC Lowers Stock Holdings in Kenvue Inc. $KVUE

Cullen Capital Management LLC reduced its position in Kenvue Inc. (NYSE:KVUE) by 72.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,484,940 shares of the company’s stock after selling 6,565,339 shares during the quarter. Cullen Capital Management LLC’s holdings in Kenvue were worth $52,010,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Kenvue by 39.2% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,030 shares of the company’s stock valued at $696,000 after purchasing an additional 8,178 shares during the period. Vestmark Advisory Solutions Inc. increased its holdings in shares of Kenvue by 119.5% in the first quarter. Vestmark Advisory Solutions Inc. now owns 21,946 shares of the company’s stock worth $526,000 after purchasing an additional 11,950 shares during the period. Horizon Investments LLC raised its position in shares of Kenvue by 5.5% in the first quarter. Horizon Investments LLC now owns 28,406 shares of the company’s stock worth $681,000 after buying an additional 1,489 shares in the last quarter. Aberdeen Group plc boosted its stake in Kenvue by 1.8% during the first quarter. Aberdeen Group plc now owns 666,047 shares of the company’s stock valued at $15,752,000 after buying an additional 11,710 shares during the period. Finally, Boston Family Office LLC grew its position in Kenvue by 9.7% during the first quarter. Boston Family Office LLC now owns 12,512 shares of the company’s stock worth $300,000 after buying an additional 1,109 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of Kenvue stock opened at $17.32 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $25.17. The company has a fifty day moving average of $16.20 and a 200-day moving average of $19.06. The stock has a market capitalization of $33.18 billion, a price-to-earnings ratio of 23.09 and a beta of 0.59.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The business had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.83 billion. During the same period in the previous year, the firm posted $0.28 earnings per share. The firm’s revenue for the quarter was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were issued a dividend of $0.2075 per share. The ex-dividend date was Wednesday, November 12th. This represents a $0.83 annualized dividend and a yield of 4.8%. Kenvue’s dividend payout ratio is currently 110.67%.

Analysts Set New Price Targets

Several analysts have weighed in on KVUE shares. Jefferies Financial Group lowered their price target on Kenvue from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Monday, October 27th. Edward Jones lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Citigroup cut their price target on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, October 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a research report on Tuesday, October 14th. Finally, UBS Group reduced their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $20.23.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.